GEN Exclusives

More »

GEN Poll

More »
Jun 05, 2012

Drug Repurposing

On June 12, NIH’s National Center for Advancing Translational Sciences (NCATS) will disclose its list of molecules for repurposing under a joint agency-industry pilot program. The initiative, Discovering New Therapeutic Uses for Existing Molecules, was announced last month. Pfizer, AstraZeneca, and Eli Lilly have agreed to allow researchers to study some of their shelved compounds, in hopes of advancing the understanding of various disease mechanism as well as finding new indications. Additional pharma companies may join, increasing the number of shelved compounds available for study.

How successful will NCATS' new pilot program prove in reviving at least some shelved compounds?

Very
 
  29.0%
Somewhat
 
  38.7%
Not Very
 
  29.0%
Undecided
 
  3.2%

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Tackling the Global Problem of Fake Medicines

Policy proposals to address the growing global problem of fake medicines include a global agreement, similar to the Framework Convention on Tobacco Control, and stricter national laws to prosecute those who knowingly sell counterfeit medicines. Do you think these steps will be successful?

More »